Search

Luca SANGIORGI

Luca SANGIORGI

Director of the Department: Rare Skeletal Diseases, Rizzoli Orthopaedic Institute

Currently:

Director of:

  • IOR Rare Skeletal Diseases ,
  • five National Registers of Rare Disease

Coordinator of:

  • ERN BOND that includes 52 Centres of Excellence for the treatment of Rare Bone Disorders in 20 EU Member States. Within the ERN Coordinators Group he is one of the co-chairs of the ERN Research Working Group (past coordinator).
  • Rizzoli Bone Rare Disease Center
  • Emilia Romagna Region Hub and Spoke Network on Rare Bone Disorders.

Past:

  • Medical degree from the University of Bologna,
  • PhD in Clinical Genetics at “La Sapienza” University of Rome,
  • Master Degree in Research Promotion and Governance in Hospital Trusts and Local Health Units at the University of Modena and Reggio Emilia,
  • Visiting Scientist at the Molecular Oncology Section, Paediatric Branch of the National Cancer Institute in Maryland (USA). 

Italian Ministry of Health

Corrisponding person for Rizzoli Institute acting as Competent Authority for the “Hs-g-22-16.02 Direct grants to Member States Authority: support ERNs integration to the National Healthcare Systems of Member States”.

Biobanks:

Currently:

Director of :

  • BIOGEN, rare bone disorders biobank

Coordinator of:

  • Telethon Network of Genetic Biobanks (TNGB).
  • Biological Resources Centre (CRB) of the Rizzoli Institute
  • Rare Diseases working group of the Italian National Node of BBMRI (BBMRI.it)

Past:

Italian representative in the Assembly of Member States (AoM) of BBMRI ERIC (Biobanking and Biomolecular Resources Research Infrastructure European Research Infrastructure Consortium) from January 2013 to December 2018 serving in different responsibility positions of BBMRI ERIC Steering Committee (including Chair of the Assembly of Member States).

EMA:

Currently:

  • Member of the EnprEMA (European Network on Pediatric Research at EMA) network

Past:

  • Alternate of the Representative of Italian Government for the Committee for Advanced Therapies (CAT) of the European Medicine Agency (EMA) up to December 2017.

Current Research Projects :

  • REMEDI4ALL establishing an European Platform on drug repurposing (co-leader of the demonstration project MOI-A)
  • ERICA Joint Action on ERN research (co-leader of WP4 on Clinical Trials)
  • Connect for Children (C4C)
  • European Joint Projects on Rare Diseases WP 20 (Clinical Trial support)
  • Telethon support grant for TNGB

Scientific Societies

Member of national and international medical and scientific societies, he has been appointed President of Connective Tissue Oncology Society and International Skeletal Dysplasia Society.

Patient’s Organizations

Member of scientific committees of European and National Patients Organizations.